Published in final edited form as:

Metabolism. 2012 April ; 61(4): 577–582. doi:10.1016/j.metabol.2011.09.008.

Short-term walnut consumption increases circulating total adiponectin and apolipoprotein-A concentrations, but does not affect markers of inflammation or vascular injury in obese humans with the metabolic syndrome: data from a double-blinded, randomized, placebo-controlled study

Konstantinos N. Aronis, MD¹, Maria T. Vamvini, MD¹, John P. Chamberland, BS^{1,4}, Laura L. Sweeney, MD¹, Aoife M. Brennan, MD, MS¹, Faidon Magkos, PhD^{1,2}, and Christos S. Mantzoros, MD, DSc^{1,3,4}

¹Division of Endocrinology, Diabetes and Metabolism, Department of Internal Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA

²Department of Nutrition and Dietetics, Harokopio University, Athens, Greece

³Department of Environmental Health, Harvard School of Public Health, Boston, MA

⁴Section of Endocrinology, Department of Internal Medicine, VA Boston Healthcare System, Harvard Medical School, Boston, MA

Abstract

Background/Objective—Long-term consumption of walnuts is associated with lower cardiovascular disease risk in epidemiological studies, possibly through improvements in lipid profile and endothelial function. It remains to be elucidated how soon after initiation of walnut consumption beneficial effects on lipid profile and biomarkers of inflammation or vascular injury can be observed.

Material/Methods—Fifteen obese subjects (9 men and 6 women; age: 58 ± 2.5 years; body mass index: 36.6 ± 1.7 kg/m²) with the metabolic syndrome participated as inpatients in a randomized, double-blinded, placebo-controlled crossover study involving short-term placebo or walnut-enriched diet (48 g per day for 4 days). Apolipoproteins and markers of inflammation and vascular injury were measured before and after consumption of the experimental diets.

Results—Consumption of walnuts was associated with a statistically significant increase in serum apolipoprotein A concentrations ($P=0.03$), but did not affect circulating levels of fetuin A, resistin, C-reactive protein, serum amyloid A, soluble intercellular adhesion molecules 1 and 3,

© 2011 Elsevier Inc. All rights reserved.

Correspondence and Reprints directed to: Christos Mantzoros, MD, DSc, FACP, FACE, Professor of Medicine, Harvard Medical School, Professor in Environmental Health, Harvard School of Public Health Chief, Endocrinology Section, VA Boston Healthcare System, Director Human Nutrition Unit, Div. of Endocrinology, Diabetes and Metabolism, Joslin and Beth Israel Deaconess Medical Center, Editor-in-Chief, *Metabolism*, Clinical and Experimental, 330 Brookline Avenue FD-876, Boston, MA 02215, tel: 617-667-8630, fax: 617-667-8634, cmantzor@bidmc.harvard.edu.

Disclosure summary: The authors have nothing to disclose.

The authors have no conflicts of interest.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

soluble vascular cell adhesion protein 1, interleukins 6 and 8, tumor necrosis factor alpha, E-selectin, P-selectin, and thrombomodulin.

Conclusions—Four days of walnut consumption (48 g per day) leads to mild increases in apolipoprotein-A concentrations, changes that may precede and lead the beneficial effects of walnuts on lipid profile in obese subjects with the metabolic syndrome.

Keywords

Walnuts; endothelial function; adiponectin; short-term; apolipoprotein A; fetuin-A; resistin

Introduction

Cardiovascular disease (CVD) is a leading cause of death and disability in the United States. Increased consumption of highly processed foods and reduced consumption of whole grains and nuts has been associated with elevated CVD risk. Conversely, habitual nut consumption has been consistently associated with reduced CVD risk, regardless of the clinical endpoint used, i.e. nonfatal myocardial infarction, fatal coronary incident, or sudden cardiac death. For instance, we have previously shown, in the context of a large epidemiological study, that during 54,656 person-years of follow-up, frequent nut consumption was inversely associated with total CVD risk. Walnuts are the most popular type of nuts consumed. The mechanisms responsible for the beneficial effects of dietary walnuts are not entirely clear, but favorable changes in blood lipid profile are likely to be involved. We have observed that increasing nut consumption is significantly associated with a more favorable plasma lipid profile, including lower LDL cholesterol, non-HDL cholesterol, total cholesterol, and apolipoprotein-B-100 concentrations, but we did not observe significant associations with HDL cholesterol or inflammatory markers. Furthermore, we have previously demonstrated that increased consumption of nuts is positively associated with plasma adiponectin concentrations in diabetic women.

These observational studies cannot address whether the beneficial effects of dietary walnuts on lipid profile are causal and/or whether they occur acutely or require long-term consumption. Moreover, the underlying mechanisms through which walnuts exert their beneficial effects remain to be elucidated. Limited evidence also indicates that relatively long-term walnut consumption improves endothelial function in hypercholesterolemic patients, an effect possibly linked to improvements in several inflammatory, oxidation and vascular injury biomarkers. Interestingly, recent studies have demonstrated that walnut-induced improvements in endothelial function and antioxidant status manifest acutely, even just after a single walnut-containing meal. There is currently no data available regarding the presence and/or the timing of any short-term effects of dietary walnuts on lipid profile and on markers of inflammation (e.g., interleukins, TNF- α) and vascular injury (e.g., selectins, ICAM, VCAM) in humans. Importantly, there are no studies on the effects of dietary walnuts on the levels of these biomarkers in patients with the metabolic syndrome which is characterized by endothelial dysfunction, systemic inflammation, and insulin resistance.

The aim of the present study was thus to evaluate the effect of short-term (4 days) walnut consumption on lipid profile and circulating markers of insulin resistance, inflammation and vascular injury in obese subjects with the metabolic syndrome.

Materials and Methods

Subjects and Study Design

Fifteen obese subjects (9 men; 13 Caucasian; age: 58 ± 2.5 years; body mass index: 36.6 ± 1.7 kg/m²; waist circumference: 117 ± 2.7 cm) with the metabolic syndrome, as defined by

the 2006 International Diabetes Federation criteria, were enrolled in a randomized, double-blinded, placebo-controlled crossover study of short-term walnut or placebo consumption. The details of the study design have been previously described. The aims of this paper were the focus of supplemental competitive grant application which was submitted and funded after the original study had been published. Briefly, two different isocaloric diets, one with 48 g of walnuts daily, incorporated into a liquid meal to allow for blinding of the subjects, and one without walnuts (placebo), but otherwise with the same macronutrient composition, were administered for 4 days in a randomized, double-blinded fashion during two different inpatient visits in the General Clinical Research Center (GCRC). The two 4-day inpatient visits were spaced one month apart to achieve adequate washout. All subjects were asked to avoid walnut intake for 3 weeks before randomization and throughout the washout period. Before starting the study, subjects were evaluated using questionnaires on whether they could distinguish the walnut versus the placebo diet, and we found they could not. Blood samples were collected before and after 4 days of diet consumption (walnut or placebo), following 12 hours of fasting, and serum was prepared and stored in -80°C until analyses. The study was approved by the Institutional Review Board of the Beth Israel Deaconess Medical Center and all subjects gave written informed consent prior to participating in the study.

Biochemical Measurements

Commercially available immunoassays were used to determine the concentrations of total and high-molecular weight (HMW) adiponectin (Alpco Multimeric Adiponectin ELISA; Alpco, Salem, NH), resistin (Alpco, Resistin ELISA; Alpco, Salem, NH) and fetuin-A (Bio Vendor, Human Fetuin-A ELISA; Biovendor LCC, Candler, NC) in serum. In order to measure the HMW fraction of adiponectin, samples were pretreated with Protease II that degrades the low- and medium-molecular weight isoforms of adiponectin, for 20 minutes at 37°C . The serum concentrations of granulocyte macrophage colony-stimulating factor (GM-CSF), interferon gamma ($\text{IFN-}\gamma$), interleukin 1 beta ($\text{IL-1}\beta$), IL-2, IL-6, IL-8, IL-10, IL-12p70, and tumor necrosis factor alpha ($\text{TNF-}\alpha$) were determined with the MSD Human Ultra-Sensitive Pro-inflammatory 9-plex electrochemiluminescent (ECL) assay (MSD: Meso Scale Discovery, Gaithersburg, MD); thrombomodulin, intercellular adhesion molecule (ICAM)-3, E-selectin and P-selectin levels were measured with the MSD Vascular Injury Panel – I ECL assay; and serum amyloid A (SAA), C-reactive protein (CRP), vascular cell adhesion protein (VCAM)-1 and ICAM-1 concentrations were determined with the MSD Vascular Injury Panel - II ECL assay. Samples were run as duplicates and measurements with coefficient of variation (CV) $<15\%$ were considered acceptable. Apolipoproteins (Apo) A and B were analyzed with the automated Cobas c311 chemical analyzer (Roche, Indianapolis, IN).

Statistical Analysis

Statistical analysis was performed with Stata v.11.2 (Stata Corp. College Station, TX). Normality was examined with the Shapiro – Wilks statistic. Most variables were skewed, hence non-parametric tests were used and the results are presented as median and quartiles. Comparisons between the first and last day of each diet (walnut and placebo) were made using the Wilcoxon Signed Rank test. Comparisons across conditions were also performed with the Wilcoxon Signed Rank test, due to the crossover design of the study. All tests were two-sided and the alpha criterion was set at the 0.05 level.

Results

Total adiponectin concentration measured using the Alpco assay employed herein increased significantly after 4 days of walnut consumption, from 3.42 (2.49–4.78) $\mu\text{g/mL}$ to 3.93

(1.97–4.31) $\mu\text{g/mL}$ ($P = 0.03$), but HMW adiponectin or the HMW/total adiponectin ratio did not change (Table 1). ApoA concentration increased significantly after the walnut diet, from 113.00 (108.90–121.60) mg/dL to 115.10 (91.90–125.30) mg/dL ($P = 0.038$), whereas ApoA concentration decreased significantly after the placebo diet, from 114.60 (102.10–133.60) mg/dL to 106.50 (91.10–119.30) mg/dL ($P = 0.003$). ApoB concentration and the ApoA/ApoB ratio did not change significantly (Table 2). The circulating concentrations of fetuin A and resistin did not change significantly with walnut consumption (Table 1). The concentrations of CRP, SAA, soluble ICAM-1 and ICAM-3, soluble VCAM-1, IL-6, IL-8, TNF- α , E-selectin, P-selectin, and thrombomodulin did not change with 4 days of walnut consumption (Table 2). The levels of GM-CSF, IFN- γ IL-1 β , IL2, IL-10 and IL12p70 were not detectable in our samples.

Discussion

Observational epidemiological studies have been remarkably consistent in demonstrating a lower risk of CVD and more favorable outcomes in patients with diabetes and the metabolic syndrome, associated with increased nut consumption. We have previously demonstrated that frequent nut consumption is inversely associated with age-adjusted CVD risk in the setting of a large epidemiological study with 54,656 person-years of follow-up. Additionally, even after adjustment for conventional CVD risk factors, consumption of at least 5 servings/week of nuts or peanut butter remained significantly associated with a lower risk of CVD by almost 50% [serving size, 28 g (1 ounce) for nuts and 16 g (1 tablespoon) for peanut butter].

Recent studies have proposed that the various adiponectin multimers have different target tissues and/or different biological effects. The HMW isoform may mediate the majority of adiponectin's effects on the liver, endothelial cells and probably also skeletal muscle, whereas the trimers and full-length monomeric forms are responsible for other actions in various tissues. Moreover, the HMW isoform of adiponectin is considered to be responsible for its pro-inflammatory actions while the LMW isoform for its anti-inflammatory ones. Lack of an effect of walnuts to alter HMW adiponectin may explain the lack of its effect to alter inflammatory markers. Although the above underscore the need to consider adiponectin isoforms when studying its actions and functions, we have previously shown that in terms of in vivo whole body insulin sensitivity, total and HMW adiponectin are comparably good predictors without any major difference in their predictive value. In addition to the improvement of insulin sensitivity, adiponectin has also been proposed to have cardio-protective and anti-neoplastic properties.

In this interventional study, we demonstrate that short-term walnut consumption led to a statistically significant increase in the concentration of circulating total adiponectin by ~15%, while it did not affect the HMW isoform and/or resistin or fetuin-A levels. This is in agreement with previous long-term observational studies reporting that nut consumption is associated with higher adiponectin concentrations. In contrast, despite demonstrating a similar trend, we failed to show statistically significant changes in adiponectin, measured using a Linco assay, after short term walnut administration (16). Adiponectin is an adipocyte-secreted insulin sensitizer that improves insulin sensitivity and decreases inflammation. Thus, the observed increase of adiponectin concentration which was not very pronounced and which achieved significance only when measured using one of the available assays which apparently has the highest discriminatory ability, might reflect an initial phase of pre-clinical improvement of insulin sensitivity. Total adiponectin concentrations are not significantly different in predicting insulin resistance, compared to HMW-adiponectin, with higher adiponectin levels being inversely associated with risk for developing diabetes later in life. These initial findings on adiponectin levels need to be studied further.

We also studied several other adipokines which have been proposed to be markers of vascular health. Resistin is an adipose tissue-derived pro-inflammatory cytokine that directly activates endothelial cells, inducing the release of various chemokines, and is associated with insulin resistance, inflammation and cardiovascular disease. Fetuin-A is a liver-derived molecule that directly modulates insulin resistance and regulates the production of endogenous inflammatory cytokines and adipocytokines. All these hormones contribute towards the regulation of insulin sensitivity and endothelial function and ultimately regulate the balance between cardiovascular health and disease. Since levels of resistin and fetuin A remained unchanged, we propose that the increase of adiponectin concentration described herein is the first observed effect of walnut consumption that ultimately leads to the long-term improvement of the cardiovascular risk profile that is associated with walnut consumption.

Our data are consistent with the results of a long-term interventional study in women with polycystic ovary syndrome (PCOS), another insulin-resistance state, in which 6 weeks of walnut consumption improved the insulin response to an oral glucose tolerance test by 26%. The results that we present herein support the notion that changes in adiponectin levels occur even with short-term walnut consumption and might precede the improvement of insulin resistance and, by extension, diabetes, cardiovascular disease and cancer. There is also mounting evidence suggesting that adiponectin has anti-inflammatory properties relevant to vascular function. For instance, adiponectin in physiological concentrations has been shown to dose-dependently inhibit TNF- α -induced cell adhesion and expression of VCAM-1, E-selectin, and ICAM-1 in human aortic endothelial cells. Nevertheless, we found no changes in the circulating levels of these latter biomarkers in serum.

It has also been suggested that favorable changes in lipid profile, which follow long-term consumption of nuts such as walnuts, could also account, at least in part, for the cardioprotective effect of walnut consumption. In a recent meta-analysis, 3–6 weeks of walnut consumption has been demonstrated to increase HDL cholesterol concentration and decrease total and LDL cholesterol and triglyceride concentrations. Circulating apolipoprotein-A represents the HDL fraction of lipoproteins and has been demonstrated to be a powerful predictor of cardiovascular disease risk. In this study, we demonstrated that walnut consumption for 4 days leads to a small, but statistically significant, increase in Apo-A concentration, that is consistent with the previously reported long-term results. Thus, this is the first study to demonstrate that the beneficial effects of walnut consumption on the lipid profile are evident even within the first 4 days of walnut consumption.

Furthermore, recent large-scale cross-sectional studies have put forth the hypothesis that favorable changes in inflammatory markers relating to atherosclerosis, such as reductions in CRP and IL-6, could also contribute to the observed reduction in CVD risk associated with nut consumption. Smaller interventional studies have demonstrated that, besides its hypocholesterolemic effect, relatively prolonged walnut consumption (40–65 g per day for 4–6 weeks) also favorably alters several inflammatory and vascular injury biomarkers, such as CRP, VCAM-1, ICAM-1 and E-selectin and improves endothelial function in hypercholesterolemic subjects. Remarkably, an improvement in endothelial function by ~25% was also apparent even after a 40g single walnut-containing meal, but this effect was largely independent of changes in oxidative stress, inflammatory and vascular health biomarkers. Consistent with these observations, we observed no changes in a large array of circulating markers of inflammation and vascular injury after 4 days of walnut consumption. Since the daily amount of walnuts consumed was rather similar in all the previous studies as well as the present one (40–65 g per day), the different results between studies of short-term and long-term walnut consumption are likely due to the length of the dietary intervention (4 days as opposed to 4 weeks). Differences in baseline lipid profile and extent of

endothelial dysfunction could also be responsible for these discrepant results, since the walnut-induced improvement in endothelial function has only been demonstrated in hypercholesterolemic and not in normocholesterolemic subjects. Only 4 of our subjects were hypercholesterolemic, and this may partly account for the lack of an effect of dietary walnuts on circulating markers of inflammation and vascular injury. It is possible that walnut consumption may be inducing changes in the expression of pro-inflammatory genes at intracellular sites (e.g. reduces TNF- α and IL-6 mRNA in peripheral blood mononuclear cells) that do not manifest as changes in the concentrations of these biomarkers in serum. Alternatively, it is also possible that more than 4 days are needed for the beneficial effects of the intervention and/or increased adiponectin concentration to manifest. This remains to be examined by longer, dose-response studies in the future.

Major strengths of our study include its crossover, randomized, placebo-controlled and double-blinded design. Laboratory assays were performed using state of the art instruments by blinded technicians unaware of the hypotheses underlying the study. The major limitation is the lack of any hard clinical measurements of endothelial dysfunction and vascular health, but 4 days would be too early to detect such changes. Also, we only evaluated the circulating levels of inflammatory and vascular injury biomarkers and these may not necessarily reflect changes in biological function. Furthermore, the specific nutrients in walnuts responsible for the observed beneficial effects remain unknown. Walnuts contain a wide array of nutrients with relevance to cardiovascular health. They are particularly rich sources of the polyunsaturated fatty acids linoleic and α -linolenic acids, and also contain high amounts of dietary fiber, arginine-rich protein, potassium, copper, and magnesium, as well as antioxidant vitamin E and other compounds with biological activity such as flavonoids, other polyphenols, and sterols. It is thus likely that the effects of walnut consumption on CVD risk stem from the combined actions of more than one nutrient on many biological functions. It is also possible that their effect on markers studied herein could be mediated through changes in appetite and short term caloric intake but these possibilities could not be assessed directly and/or through multivariable adjustment in this study due to limitations imposed by the dataset.

In conclusion, the results of this randomized, double-blinded, placebo-controlled, crossover study suggest that short-term consumption of walnuts (48 g per day for 4 days) improves lipid profile, by increasing apolipoprotein A concentration, suggesting that walnuts exert their beneficial effect on lipid metabolism even within 4 days of consumption. The apparent increase in the circulating concentration of the endogenous insulin sensitizer, adiponectin, suggests that adiponectin might be the link to the long-term beneficial effects of walnut consumption on cardiovascular disease, insulin resistance, and neoplasia. Longer-term studies could provide further insight into the mechanisms through which dietary walnuts exert their beneficial actions.

Acknowledgments

Grant Support: The project described was supported by Grant Number M01-RR-01032-328840 to the Harvard Clinical and Translational Science Center, from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. Funding was also received from the National Institute of Diabetes and Digestive and Kidney Diseases (grant DK081913), and the California Walnut Commission.

KNA conducted research, analyzed the data and wrote the paper, MTV and JPC conducted research LLS and AMB contributed to the initial phase of this study. FM supervised analyses and wrote initial drafts of the paper and CSM designed and supervised the study and wrote the paper. All authors have read and approved the final manuscript

References

1. Kung HC, Hoyert DL, Xu J, Murphy SL. Deaths: final data for 2005. Natl Vital Stat Rep. 2008; 56:1–120. [PubMed: 18512336]
2. Nettleton JA, Polak JF, Tracy R, Burke GL, Jacobs DR Jr. Dietary patterns and incident cardiovascular disease in the Multi-Ethnic Study of Atherosclerosis. Am J Clin Nutr. 2009; 90:647–654. [PubMed: 19625679]
3. Sabate J, Ang Y. Nuts and health outcomes: new epidemiologic evidence. Am J Clin Nutr. 2009; 89:1643S–1648S. [PubMed: 19321572]
4. Li TY, Brennan AM, Wedick NM, Mantzoros C, Rifai N, Hu FB. Regular consumption of nuts is associated with a lower risk of cardiovascular disease in women with type 2 diabetes. The Journal of nutrition. 2009; 139:1333–1338. [PubMed: 19420347]
5. Jenab M, Sabate J, Slimani N, Ferrari P, Mazuir M, Casagrande C, Deharveng G, Tjonneland A, Olsen A, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Boeing H, Weikert C, Linseisen J, Rohrmann S, Trichopoulou A, Naska A, Palli D, Sacerdote C, Tumino R, Mattiello A, Pala V, Bueno-de-Mesquita HB, Ocke MC, Peeters PH, Engeset D, Skeie G, Jakszyn P, Ardanaz E, Quiros JR, Chirlaque MD, Martinez C, Amiano P, Berglund G, Palmqvist R, van Guelpen B, Bingham S, Key T, Riboli E. Consumption and portion sizes of tree nuts, peanuts and seeds in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohorts from 10 European countries. Br J Nutr. 2006; 96(Suppl 2):S12–23. [PubMed: 17125528]
6. Banel DK, Hu FB. Effects of walnut consumption on blood lipids and other cardiovascular risk factors: a meta-analysis and systematic review. Am J Clin Nutr. 2009; 90:56–63. [PubMed: 19458020]
7. Mantzoros CS, Williams CJ, Manson JE, Meigs JB, Hu FB. Adherence to the Mediterranean dietary pattern is positively associated with plasma adiponectin concentrations in diabetic women. The American journal of clinical nutrition. 2006; 84:328–335. [PubMed: 16895879]
8. Ros E, Nunez I, Perez-Heras A, Serra M, Gilabert R, Casals E, Deulofeu R. A walnut diet improves endothelial function in hypercholesterolemic subjects: a randomized crossover trial. Circulation. 2004; 109:1609–1614. [PubMed: 15037535]
9. Salas-Salvado J, Casas-Agustench P, Murphy MM, Lopez-Urriarte P, Bullo M. The effect of nuts on inflammation. Asia Pac J Clin Nutr. 2008; 17(Suppl 1):333–336. [PubMed: 18296371]
10. Zhao G, Etherton TD, Martin KR, West SG, Gillies PJ, Kris-Etherton PM. Dietary alpha-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. J Nutr. 2004; 134:2991–2997. [PubMed: 15514264]
11. Cortes B, Nunez I, Cofan M, Gilabert R, Perez-Heras A, Casals E, Deulofeu R, Ros E. Acute effects of high-fat meals enriched with walnuts or olive oil on postprandial endothelial function. J Am Coll Cardiol. 2006; 48:1666–1671. [PubMed: 17045905]
12. Torabian S, Haddad E, Rajaram S, Banta J, Sabate J. Acute effect of nut consumption on plasma total polyphenols, antioxidant capacity and lipid peroxidation. J Hum Nutr Diet. 2009; 22:64–71. [PubMed: 19192028]
13. Rizvi AA. Cytokine biomarkers, endothelial inflammation, and atherosclerosis in the metabolic syndrome: emerging concepts. Am J Med Sci. 2009; 338:310–318. [PubMed: 19726972]
14. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutr Metab Cardiovasc Dis. 2010; 20:140–146. [PubMed: 19833491]
15. Holt RI. International Diabetes Federation re-defines the metabolic syndrome. Diabetes Obes Metab. 2005; 7:618–620. [PubMed: 16050956]
16. Brennan AM, Sweeney LL, Liu X, Mantzoros CS. Walnut consumption increases satiety but has no effect on insulin resistance or the metabolic profile over a 4-day period. Obesity (Silver Spring). 2010; 18:1176–1182. [PubMed: 19910942]
17. Bluher M, Brennan AM, Kelesidis T, Kratzsch J, Fasshauer M, Kralisch S, Williams CJ, Mantzoros CS. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays. Diabetes Care. 2007; 30:280–285. [PubMed: 17259495]

18. Fu Q, Zhu J, Van Eyk JE. Comparison of multiplex immunoassay platforms. *Clin Chem*. 2010; 56:314–318. [PubMed: 20022982]
19. Feldman EB. The scientific evidence for a beneficial health relationship between walnuts and coronary heart disease. *J Nutr*. 2002; 132:1062S–1101S. [PubMed: 11983840]
20. Kendall CW, Josse AR, Esfahani A, Jenkins DJ. Nuts, metabolic syndrome and diabetes. *Br J Nutr*. 2010; 104:465–473. [PubMed: 20441672]
21. Cohen AE, Johnston CS. Almond ingestion at mealtime reduces postprandial glycemia and chronic ingestion reduces hemoglobin A(1c) in individuals with well-controlled type 2 diabetes mellitus. *Metabolism*. 2011; 60:1312–1317. [PubMed: 21489570]
22. Simpson F, Whitehead JP. Adiponectin--it's all about the modifications. *Int J Biochem Cell Biol*. 2010; 42:785–788. [PubMed: 20044026]
23. Trujillo ME, Scherer PE. Adiponectin--journey from an adipocyte secretory protein to biomarker of the metabolic syndrome. *J Intern Med*. 2005; 257:167–175. [PubMed: 15656875]
24. Ouchi N, Kobayashi H, Kihara S, Kumada M, Sato K, Inoue T, Funahashi T, Walsh K. Adiponectin stimulates angiogenesis by promoting cross-talk between AMP-activated protein kinase and Akt signaling in endothelial cells. *J Biol Chem*. 2004; 279:1304–1309. [PubMed: 14557259]
25. Hada Y, Yamauchi T, Waki H, Tsuchida A, Hara K, Yago H, Miyazaki O, Ebinuma H, Kadowaki T. Selective purification and characterization of adiponectin multimer species from human plasma. *Biochem Biophys Res Commun*. 2007; 356:487–493. [PubMed: 17368570]
26. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. *J Clin Invest*. 2006; 116:1784–1792. [PubMed: 16823476]
27. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. *Nat Rev Immunol*. 2006; 6:772–783. [PubMed: 16998510]
28. Shibata R, Ouchi N, Murohara T. Adiponectin and cardiovascular disease. *Circ J*. 2009; 73:608–614. [PubMed: 19261992]
29. Barb D, Williams CJ, Neuwirth AK, Mantzoros CS. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. *The American journal of clinical nutrition*. 2007; 86:s858–866. [PubMed: 18265479]
30. Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. *The American journal of clinical nutrition*. 2010; 91:258S–261S. [PubMed: 19906806]
31. Heidemann C, Sun Q, van Dam RM, Meigs JB, Zhang C, Tworoger SS, Mantzoros CS, Hu FB. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women. *Annals of internal medicine*. 2008; 149:307–316. [PubMed: 18765700]
32. Kougias P, Chai H, Lin PH, Yao Q, Lumsden AB, Chen C. Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease. *J Surg Res*. 2005; 126:121–129. [PubMed: 15916985]
33. Gomez-Ambrosi J, Fruhbeck G. Evidence for the involvement of resistin in inflammation and cardiovascular disease. *Curr Diabetes Rev*. 2005; 1:227–234. [PubMed: 18220599]
34. Hennige AM, Staiger H, Wicke C, Machicao F, Fritsche A, Haring HU, Stefan N. Fetuin-A induces cytokine expression and suppresses adiponectin production. *PLoS One*. 2008; 3:e1765. [PubMed: 18335040]
35. Kalgaonkar S, Almario RU, Gurusinghe D, Garamendi EM, Buchan W, Kim K, Karakas SE. Differential effects of walnuts vs almonds on improving metabolic and endocrine parameters in PCOS. *Eur J Clin Nutr*. 2011; 65:386–393. [PubMed: 21157477]
36. Mantzoros CS, Li T, Manson JE, Meigs JB, Hu FB. Circulating adiponectin levels are associated with better glycemic control, more favorable lipid profile, and reduced inflammation in women with type 2 diabetes. *J Clin Endocrinol Metab*. 2005; 90:4542–4548. [PubMed: 15914524]
37. Shetty GK, Economides PA, Horton ES, Mantzoros CS, Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. *Diabetes Care*. 2004; 27:2450–2457. [PubMed: 15451915]

38. Matarese G, Mantzoros C, La Cava A. Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis. *Curr Pharm Des.* 2007; 13:3676–3680. [PubMed: 18220805]
39. Williams CJ, Mitsiades N, Sozopoulos E, Hsi A, Wolk A, Nifli AP, Tseleni-Balafouta S, Mantzoros CS. Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. *Endocr Relat Cancer.* 2008; 15:289–299. [PubMed: 18310295]
40. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systematic review. *Br J Cancer.* 2006; 94:1221–1225. [PubMed: 16570048]
41. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. *J Natl Cancer Inst.* 2005; 97:1688–1694. [PubMed: 16288122]
42. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, Mantzoros CS. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. *Cancer Epidemiol Biomarkers Prev.* 2007; 16:308–313. [PubMed: 17301264]
43. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamoto Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. *Circulation.* 1999; 100:2473–2476. [PubMed: 10604883]
44. Mukuddem-Petersen J, Oosthuizen W, Jerling JC. A systematic review of the effects of nuts on blood lipid profiles in humans. *J Nutr.* 2005; 135:2082–2089. [PubMed: 16140880]
45. Chan DC, Ng TW, Watts GF. Apolipoprotein A-II: Evaluating its significance in dyslipidaemia, insulin resistance, and atherosclerosis. *Ann Med.* 2011
46. Jiang R, Jacobs DR Jr, Mayer-Davis E, Szklo M, Herrington D, Jenny NS, Kronmal R, Barr RG. Nut and seed consumption and inflammatory markers in the multi-ethnic study of atherosclerosis. *Am J Epidemiol.* 2006; 163:222–231. [PubMed: 16357111]
47. Jimenez-Gomez Y, Lopez-Miranda J, Blanco-Colio LM, Marin C, Perez-Martinez P, Ruano J, Paniagua JA, Rodriguez F, Egido J, Perez-Jimenez F. Olive oil and walnut breakfasts reduce the postprandial inflammatory response in mononuclear cells compared with a butter breakfast in healthy men. *Atherosclerosis.* 2009; 204:e70–76. [PubMed: 18952211]
48. Ros E. Nuts and novel biomarkers of cardiovascular disease. *Am J Clin Nutr.* 2009; 89:1649S–1656S. [PubMed: 19321561]

Table 1

Serum concentrations of adiponectin, fetuin-A and resistin at baseline and after 4 days of either placebo or walnut consumption. Results displayed as median and 25th–75th interquartile range (n = 15).

	Placebo		P	Walnut		P
	Day 1	Day 4		Day 1	Day 4	
Total adiponectin (µg/mL)	3.27 (2.37–4.92)	3.06 (2.04–4.51)	0.16	3.42 (2.49–4.78)	3.93 (1.97–4.31)	0.03
HMW adiponectin (µg/mL)	1.73 (0.58–2.27)	1.42 (0.32–2.32)	0.01	1.82 (0.49–2.53)	1.49 (0.66–1.97)	0.11
% HMW adiponectin	45.8 (26.2–52.3)	40.1 (19.7–53.5)	0.38	50.9 (21.1–58.5)	36.7 (29.1–55.1)	0.86
Fetuin A (µg/mL)	261.03 (237.70–71.59)	265.40 (205.04–442.99)	0.91	264.51 (191.94–335.04)	258.25 (2435.41–332.90)	0.28
Resistin (ng/mL)	4.39 (2.34–6.97)	4.34 (2.83–6.00)	0.43	3.27 (2.50–5.62)	4.91 (3.04–6.83)	0.05

Serum concentrations of inflammatory markers, markers of vascular injury, and apolipoproteins at baseline and after 4 days of either placebo or walnut consumption. Results displayed as median and 25th–75th interquartile range (n = 15).

Table 2

	Placebo		P	Walnut		P
	Day 1	Day 4		Day 1	Day 4	
CRP (μg/mL)	2.21 (0.52–5.85)	1.23 (0.27–3.95)	0.02	1.82 (1.09–5.08)	2.01 (0.43–3.86)	0.39
SAA (μg/mL)	1.63 (1.48–4.28)	1.31 (1.01–3.34)	0.01	1.68 (1.09–2.29)	1.47 (1.13–2.33)	0.07
sICAM-1 (ng/mL)	184.61 (144.72–270.29)	172.32 (150.24–256.88)	0.69	177.27 (149.47–256.76)	185.10 (158.05–264.03)	0.11
sICAM-3 (ng/mL)	0.51 (0.45–0.67)	0.56 (0.36–0.73)	0.82	0.54 (0.41–0.64)	0.59 (0.42–0.67)	0.73
sVCAM-1 (ng/mL)	293.57 (209.75–402.94)	277.08 (238.54–404.56)	0.91	279.27 (206.40–422.31)	285.49 (236.47–432.57)	0.14
IL-6 (pg/mL)	1.50 (0.92–2.41)	2.10 (1.63–3.65)	0.03	1.57 (1.13–2.58)	1.78 (1.34–2.78)	0.02
IL-8 (pg/mL)	6.69 (3.02–11.00)	6.21 (3.10–16.46)	0.36	5.70 (3.46–8.46)	5.58 (3.34–12.80)	0.97
TNF-α (pg/mL)	7.76 (5.48–10.38)	7.59 (5.77–9.08)	0.77	6.57 (4.92–8.23)	7.22 (5.75–11.04)	0.14
E-selectin (ng/mL)	3.03 (1.91–4.77)	2.86 (1.64–4.17)	0.42	3.20 (1.91–3.91)	2.91 (1.65–4.09)	0.57
P-selectin (ng/mL)	13.16 (10.42–16.83)	14.17 (9.03–16.53)	0.77	14.78 (11.38–16.65)	13.85 (9.75–17.15)	0.82
Thrombomodulin-1 (ng/mL)	0.57 (0.44–0.65)	0.53 (0.42–0.63)	0.11	0.53 (0.46–0.69)	0.59 (0.39–0.68)	0.73
Apo A (mg/dL)	114.60 (102.10–133.60)	106.50 (91.10–119.30)	<0.01	113.00 (108.90–121.60)	115.10 (91.90–125.30)	0.03
Apo B (mg/dL)	74.80 (66.60–107.90)	70.30 (59.70–101.30)	0.28	82.20 (70.00–114.00)	78.30 (63.40–100.40)	0.21
ApoA/ApoB	0.73 (0.55–0.87)	0.77 (0.48–0.87)	0.17	0.73 (0.54–0.96)	0.79 (0.53–0.99)	0.28